Not provided
Not provided
Not provided
Not provided
Business decision on June 2, 2022
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will test newly developed stimulation settings called Temporally Optimized Patterned Stimulation or TOPS, which can be used with an already implanted deep brain stimulation system. The purpose of this study is to determine if TOPS DBS can improve Parkinson's symptoms compared to Standard DBS.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TOPS1 DBS | Experimental | Participants receive TOPS1 for one week if it meets screening criteria, followed by one week each of TOPS2, TOPS3, and Standard in random order. |
|
| TOPS2 DBS | Experimental | Participants receive TOPS2 for one week if it meets screening criteria, followed by one week each of TOPS1, TOPS3, and Standard in random order. |
|
| TOPS3 DBS | Experimental | Participants receive TOPS3 for one week if it meets screening criteria, followed by one week each of TOPS1, TOPS2, and Standard in random order. |
|
| Standard DBS | Active Comparator | Participants receive Standard for one week, followed by one week each of TOPS1, TOPS2, and TOPS3 in random order. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TOPS1 DBS | Device | TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system |
|
| Measure | Description | Time Frame |
|---|---|---|
| Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III Motor score - Off medication/On DBS | Average difference between the best TOPS and Standard. The MDS-UPDRS Part III is the sum of 33 scores evaluating a set of Parkinson's disease motor symptoms on a scale from 0 to 4 points. A score of 0 indicates no symptom is present and a maximum score of 4 indicates the most severe symptom. The total scale range is 0-132, where higher scores indicate more severe symptoms. | After 1 week treatment period using each pattern |
| Study related adverse device effects | Reported AEs | After 1 week treatment period using TOPS1 |
| Study related adverse device effects | Reported AEs | After 1 week treatment period using TOPS2 |
| Study related adverse device effects | Reported AEs | After 1 week treatment period using TOPS3 |
| Study related adverse device effects | Reported AEs | After 1 week treatment period using Standard |
| Measure | Description | Time Frame |
|---|---|---|
| Home Use "On Time" | Home use Parkinson's disease motor symptom diary recording On Time without dyskinesia, On Time with non-troublesome dyskinesia, On Time with troublesome dyskinesia, Off Time, and Asleep Time. Average "On Time" difference between the best TOPS and Standard | During 1 week treatment period using each pattern |
Not provided
Key Inclusion Criteria:
Key Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Florida | Gainesville | Florida | 32608 | United States | ||
| Northwestern University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Random order of presentation of all three TOPS and Standard DBS in each participant
Not provided
Not provided
Participant and Outcomes Assessor blinded to DBS pattern in use
| TOPS2 DBS | Device | TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system |
|
| TOPS3 DBS | Device | TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system |
|
| Standard DBS | Device | Standard is the pattern of stimulation that is usually delivered clinically by a DBS system |
|
| Patient Global Impression of Improvement Rating |
Average difference in PGII between the best TOPS and Standard. Improvement is scored on a scale of 1 - 7 where 1 is Very Much Improved and 7 is Very Much Worse |
| After 1 week treatment period using each pattern |
| Parkinson's Medication Use | Parkinson's medication usage recorded in home use medication diary. Average difference between the best TOPS and Standard | During 1 week treatment period using each pattern |
| Rest Tremor - Off medication/On DBS | Measured using Kinesia One system. Average difference between the best TOPS and Standard | After 1 week treatment period using each pattern |
| Postural Tremor - Off medication/On DBS | Measured using Kinesia One system. Average difference between the best TOPS and Standard. | After 1 week treatment period using each pattern |
| Bradykinesia - Off medication/On DBS | Measured using Kinesia One system. Average difference between the best TOPS and Standard. | After 1 week treatment period using each pattern |
| Type and severity of side effects of stimulation | Proportion of participants experiencing side effects recorded in home use motor symptom diary and clinic. Average difference between the best TOPS and Standard | During 1 week treatment period using each pattern |
| Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III Motor score - On medication/On DBS | Average difference between the best TOPS and Standard. The MDS-UPDRS Part III is the sum of 33 scores evaluating a set of Parkinson's disease motor symptoms on a scale from 0 to 4 points. A score of 0 indicates no symptom is present and a maximum score of 4 indicates the most severe symptom. The total scale range is 0-132, where higher scores indicate more severe symptoms. | After 1 week treatment period using each pattern |
| Clinical Global Impression of Improvement Rating | Average difference in CGII score between the best TOPS and Standard. Improvement is scored on a scale of 1 - 7 where 1 is Very Much Improved and 7 is Very Much Worse | After 1 week treatment period using each pattern |
| Test Pattern Use Count | For each pattern, the number of subjects who go home with it and use it for the entire test period (~7-14 days) will be counted to evaluate if any patterns are more or less likely to be skipped | After 1 week treatment period using each pattern |
| Chicago |
| Illinois |
| 60611 |
| United States |
| Duke University | Durham | North Carolina | 27705 | United States |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Feb 8, 2023 | Mar 7, 2023 | 9 |
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
Not provided
Not provided